drug
(cedazuridine + decitabine)
Marketedupdated 3mo agoby Otsuka Pharmaceutical Co Ltd
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying (cedazuridine + decitabine)
- phase2Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.
- EP1Early Intervention in High Risk CCUS
- phase1Inqovi Maintenance Therapy in Myeloid Neoplasms
- phase2STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jul 7, 2027
323 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (6)
- Feb 24, 2041formulationUS 11963971
- Feb 24, 2041method-of-use (U-2866)US 12239653
- Oct 7, 2040formulationUS 12195496
- Aug 22, 2030compositionUS 82688004.0y
- Oct 16, 2028method-of-use (U-2867)US 86180752.2y
- Oct 16, 2028compositionUS 95673632.2y
FDA exclusivities (1)
- Jul 7, 2027ODE-316Orphan Drug (7y)323d
News(4)
- Cullinan tees up J&J fight—and $100M payday—as Taiho-partnered drug hits phase 3 cancer goalTaiho Pharmaceutical and Cullinan Therapeutics have celebrated a second phase 3 victory for their small-molecule EGFR inhibitor, teeing up the partners to challenge Johnson & Johnson in a lung canc…fiercebiotech · 4d ago
- Aardvark's next move after clinical hold; Alumis' verdict on Acelyrin assetPlus, news about Tenaya’s TN-401 and Taiho’s Inqovi. 📉 Aardvark to unblind rare disease trial following clinical hold: The FDA has placed a full clinical hold on the company's candidate for ...endpoints · 3mo ago
- FDA Approves Decitabine/Cedazuridine Plus Venetoclax in Newly Diagnosed AMLThe FDA has approved oral decitabine/cedazuridine plus venetoclax for newly diagnosed AML unfit for intensive chemo, based on phase 2 ASCERTAIN-V data.onclive · 3mo ago
- Dr Dinardo on the FDA Approval of Decitabine/Cedazuridine Plus Venetoclax in AMLCourtney D. DiNardo, MD, MSCE, discusses the FDA approval of decitabine/cedazuridine plus venetoclax in acute myeloid leukemia.onclive · 3mo ago
Data sources
last refreshed 8m ago
Found something off?
comments(0)
5-min edit window · permanent after that